Surrozen Business Summary

Surrozen, Inc. (SRZN) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements, research service fees from related parties, and potential success-based milestone payments. The company’s business model is centered on its proprietary SurroBody and SWAP platforms, which engineer tissue-specific antibodies to modulate the Wnt signaling pathway for organ repair and regeneration. Its primary business segments are categorized by therapeutic focus, with a lead emphasis on Ophthalmology (targeting retinal vascular diseases like SZN-8141 and SZN-8143), followed by Gastrointestinal disorders and Oncology. In the competitive landscape of regenerative medicine and antibody engineering, Surrozen competes with major players such as Novartis and specialized biotechs like AbCellera Biologics, ARS Pharmaceuticals, and Evommune, positioning itself as a pioneer in selective Wnt-pathway agonism to overcome the historical limitations of systemic Wnt modulation. Founded in 2016 by world-renowned scientists Christopher Garcia, Ph.D., Calvin Kuo, M.D., Ph.D., and Claudia Janda, Ph.D., the company is led by President and CEO Craig Parker, who brings over 30 years of biopharma leadership experience. The executive team includes CFO Andrew Maleki, COO Charles Williams, and EVP of Research Yang Li, Ph.D., alongside VP of Clinical Development Dan Chao, M.D., Ph.D., a prominent retina specialist who joined in 2025. Surrozen is backed by high-profile institutional investors including The Column Group (TCG), TCG Crossover, and Horizons Ventures. Its Board of Directors is chaired by David J. Woodhouse, Ph.D., and includes notable industry figures such as Tim Kutzkey, Ph.D. (Managing Partner at TCG) and Mace Rothenberg, M.D., ensuring a deep pedigree in translational medicine and corporate strategy.